Calcific Aortic Valve Disease — Molecular Mechanisms (CAVD)
Definition
Calcific aortic valve disease (CAVD) is the pathological fibrocalcific remodeling of aortic valve leaflets leading to calcific aortic stenosis (AS). CAVD begins with lipid infiltration and inflammation (aortic sclerosis) and progresses through osteogenic transformation of valve cells, ECM disruption, and mineral deposition. Unlike atherosclerosis — which shares many risk factors — there is currently no effective medical therapy that halts CAVD progression.
Key Concepts
Epidemiology and Risk Factors
- Age-standardized prevalence of AS: 116.3/100,000; global prevalence ↑124% from 1990–2017 sources/vhd-mechanism-aha-2024 (very high)
- Risk factors: older age, male sex, hypertension, T2DM, dyslipidemia (elevated Lp(a) particularly), smoking, elevated BMI, ESRD
- ~25% of individuals ≥65 years have aortic sclerosis (leaflet thickening without obstruction); ~1.8% progress to AS annually
- Disease initiation and disease progression are likely distinct processes — risk factors for initiation differ from those driving progression; Lp(a) is associated with disease onset but not with progression of established aortic valve calcification sources/vhd-mechanism-aha-2024 (very high)
Cellular Architecture of the Aortic Valve
- Three-layer structure: collagen-rich fibrosa (outer), proteoglycan-rich spongiosa (middle), elastin-rich ventricularis (inner, facing ventricle) sources/vhd-mechanism-aha-2024 (very high)
- Valvular endothelial cells (VECs): single-cell lining; first to be disrupted by shear and mechanical stress; disruption initiates disease cascade
- Valve interstitial cells (VICs): fibroblast-like cells, quiescent in normal valves; become activated myofibroblastic VICs in disease; capable of osteogenic differentiation; single-cell profiling identifies specific disease-driver VIC subpopulations in human CAVD
Primary Disease Cascade
- Mechanical and shear stress → VEC layer disruption → initiates inflammation, lipid infiltration, oxidative stress
- Lipid deposition (LDL-C, Lp(a)) → inflammatory cascade → osteogenic transcriptional programs in VICs
- ECM disruption → fragmented ECM fibers serve as nucleation sites for calcium and phosphate; activates mechanosensing pathways promoting osteogenic programs
- EV release (extracellular vesicles) → trapped in disrupted ECM → nucleation of hydroxyapatite microcalcifications → progressive macrocalcifications
- Calcification begins in the fibrosa, typically starting in the noncoronary cusp sources/vhd-mechanism-aha-2024 (very high)
Lipid Pathway
- Lp(a): independent causal role via Mendelian randomization; mechanism: covalently linked oxidised phospholipids → activate osteogenic transcriptional programs in VICs; autotaxin (ATX, encoded by ENPP2) metabolises Lp(a)-associated lysophosphatidylcholine → ATX gene expression elevated in CAVD VICs; autotaxin overexpression promotes valve mineralisation in murine models sources/vhd-mechanism-aha-2024 (very high)
- LDL-C: independent causal role (multivariable Mendelian randomization); association attenuated when accounting for Lp(a) — suggesting partial overlap in causal pathway
- Remnant cholesterol: associated with AS but significance attenuated when accounting for other lipids; triglycerides lose significance
- Statin paradox: strong epidemiological and genetic evidence for lipid involvement in CAVD initiation, yet statins (SALTIRE trial) showed no benefit in progression — consistent with initiation/progression being distinct processes sources/vhd-mechanism-aha-2024 (very high)
- Sortilin (genome-wide significant GWAS locus in AS; also associated with LDL-C metabolism) mediates EV loading of TNAP → calcifying extracellular vesicles
Inflammatory Pathway
- Lipid deposition → inflammatory response (early initiating event)
- IL6 intronic SNPs GWAS-implicated in calcific AS; IL-6 is downstream of NLRP3 inflammasome
- Clonal hematopoiesis of indeterminate potential (CHIP): somatic variants in hematopoietic stem cells; common in CAVD; portend worse prognosis after AVR; promote cardiovascular risk by augmenting NLRP3-mediated gene programs sources/vhd-mechanism-aha-2024 (very high)
- Interferonopathies (Singleton-Merten syndrome, ADAR-related type 1 interferonopathy): systemic type-1 interferon elevation → extreme early valve calcification phenotype — supports innate immunity involvement
Extracellular Vesicle (EV) Pathway
- EVs classified as exosomes, microparticles, or apoptotic bodies; released from VECs, VICs, and macrophages
- Outer membrane protects cargo: bioactive molecules, proteins, enzymes, microRNA
- Key mechanism: sortilin (via intracellular trafficking) → TNAP (tissue-nonspecific alkaline phosphatase, ALPL gene) loaded into EVs → released EVs trapped in collagen fibres via annexin-1 → TNAP activity generates calcium/phosphate → hydroxyapatite microcalcifications → merge to macrocalcifications visible on imaging
- Role of EVs in VHD largely understudied; bioprosthetic valves not yet examined for EV presence
Sex Differences in CAVD
- Men: predominantly calcific disease
- Women: predominantly fibrotic disease — same hemodynamic AS severity with less calcium on imaging
- X-chromosome inactivation: several genes escaping inactivation increase myofibroblast activation preferentially in women (porcine and human VIC studies) sources/vhd-mechanism-aha-2024 (very high)
- Non-White individuals: lower reported AS prevalence (possible diagnostic/access bias; most large studies focus on White individuals)
Potential Therapeutic Targets and Ongoing Trials
- Lp(a) lowering: pelacarsen (anti-sense oligonucleotide siRNA) — NCT05646381 (n=502; endpoint: AV calcium score + peak velocity) sources/vhd-mechanism-aha-2024 (very high)
- LDL-C: PCSK9 inhibitor — NCT04968509 (n=160; CT calcium score)
- Inflammation: colchicine — CHIANTI trial (n=150); COPAS pilot (n=24; NaF-PET/CT)
- Endothelial dysfunction: evogliptin (DPP4 inhibitor) — EVOID-AS (n=867)
- RAAS: ARBs — ARBAS (n=144)
- PPAR-γ: pioglitazone (n=100; 3-year mortality)
- Additional mechanistic targets: NOTCH pathway signaling; mineral nucleation (annexin-A1); epigenetic reprogramming (TERT/STAT5); cadherin-11
Knowledge Gaps
- Why does the noncoronary cusp calcify first?
- Why does the majority of aortic sclerosis never progress to hemodynamically significant AS?
- What triggers the acute transition of healthy VICs to calcifying cells?
- No faithful ex vivo or in vivo model adequately recapitulates human CAVD (murine valves contain melanocytes; ovine/porcine/bovine models require high cost)
- Sex-stratified GWASs remain underpowered
Contradictions / Open Questions
- Statin paradox: lipids are causal in CAVD initiation (Mendelian randomization) yet statins fail in progression (SALTIRE) — supports initiation/progression distinction but exact mechanistic boundary is undefined sources/vhd-mechanism-aha-2024 (very high)
- Lp(a) and progression: Lp(a) is associated with CAVD onset but NOT with progression of established aortic valve calcification (Kaiser 2022, EHJ) — potentially limits the therapeutic window for Lp(a) lowering
- Disease-initiating molecular events in early aortic sclerosis are incompletely understood; F-NaF PET imaging shows biological activity even in sclerosis without hemodynamically significant AS
Connections
- Related to concepts/Aortic-Stenosis — clinical management framework for AS
- Related to entities/Bicuspid-Aortic-Valve — BAV accelerates CAVD via abnormal shear/stress patterns
- Related to concepts/Lipoprotein-a — Lp(a) as key causal driver of CAVD initiation
- Related to concepts/Valvular-Heart-Disease — VHD overview
- Related to sources/vhd-mechanism-aha-2024